Literature DB >> 29762073

The Association of Socioeconomic Status with Severity of Glaucoma and the Impacts of Both Factors on the Costs of Glaucoma Medications: A Cross-Sectional Study in West Bengal, India.

Tutul Chakravarti1.   

Abstract

PURPOSE: To evaluate the association of socioeconomic status (SES) with severity of glaucoma and assess the impacts of both SES and disease-severity factors on the costs of glaucoma medications among different glaucoma subtypes in West Bengal, India.
METHODS: This cross-sectional study (2014-16) followed the treatment of 304 primary glaucoma patients for at least 18 months. The visual field based glaucoma staging was followed for stages 0-3; patients with field of vision <10° were categorized as stage 4 (end stage). We checked only the mean cost of glaucoma medications per patient and not "direct costs." The individuals' monthly incomes were classified into: low, moderate, and higher SES.
RESULTS: Urban residence (odds ratio [OR] 0.6, P < 0.009), higher SES (OR 0.3, P < 0.001), and higher awareness (nearly 50%, P < 0.007) significantly lowered the odds of having end-stage glaucoma. Sixty-nine percent primary angle-closure glaucoma (PACG) and 79% juvenile open-angle glaucoma (JOAG) belonged to low SES, forming the bulk of end-stage glaucoma. Overall medical cost from stage 0 to advanced stage in all subtypes rises except in primary open-angle glaucoma (POAG). Only 28% eyes from low SES were treated with branded drugs in early disease and that too declined to 16% in stage 4, while 57% higher SES used branded medications in early disease stage. Expenditure as a percent of income was the highest in JOAG (16%) followed by PACG (15%) and POAG (14%) among low SES.
CONCLUSIONS: Results indicate SES influences on disease outcome, the clinical management, and the glaucoma medication expenses in West Bengal. Medical costs of glaucoma increase with worsening disease severity; greater use of generic drugs does not always ensure direct cost savings.

Entities:  

Keywords:  brand-name medicine; cost of glaucoma medications; direct cost; end-stage glaucoma; generic medicine; socioeconomic status (SES)

Mesh:

Year:  2018        PMID: 29762073     DOI: 10.1089/jop.2017.0135

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  3 in total

Review 1.  Juvenile-onset open-angle glaucoma - A clinical and genetic update.

Authors:  Harathy Selvan; Shikha Gupta; Janey L Wiggs; Viney Gupta
Journal:  Surv Ophthalmol       Date:  2021-09-16       Impact factor: 6.197

2.  A comprehensive map of disease networks and molecular drug discoveries for glaucoma.

Authors:  Haixin Wang; Yanhui Deng; Ling Wan; Lulin Huang
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

3.  Time trends and heterogeneity in the disease burden of glaucoma, 1990-2017: a global analysis.

Authors:  Yichi Zhang; Guangming Jin; Min Fan; Yifan Lin; Xin Wen; Zijing Li; Peng Zeng; Danying Zheng; Yuqing Lan
Journal:  J Glob Health       Date:  2019-12       Impact factor: 4.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.